Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

eVusheld Assessment reaL wORld Effectiveness in the VA Health SystemCompleted
NCT05663957N/AUpdated Sep 3, 2024
Sponsor: AstraZeneca
SARS-CoV-2, COVID-19
United States
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)Completed
NCT04385368Phase 3Updated Aug 30, 2024
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
United States, Argentina, Australia, Belgium, Brazil +28 more
Harmonizing RCT-Duplicate Emulations In A Real World Replication Program (HARRP)Completed
NCT06099067N/AUpdated Aug 30, 2024
Sponsor: AstraZeneca
Type 2 Diabetes Mellitus
Sweden
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast CancerTerminated
NCT05966584Phase 2Updated Aug 29, 2024
Sponsor: Memorial Sloan Kettering Cancer Center
Breast Cancer
United States
AZD4573 as Monotherapy or in Combinations With Anti-cancer Agents in Patients With r/r PTCL or r/r cHLCompleted
NCT05140382Phase 2Updated Aug 28, 2024
Sponsor: AstraZeneca
Relapsed/Refractory Peripheral T-cell Lymphoma · Relapsed/Refractory Classical Hodgkins Lymphoma
United States, Australia, France, Italy, South Korea +3 more
PORTHOS - PORTuguese Heart Failure Observational StudyCompleted
NCT05434923N/AUpdated Aug 26, 2024
Sponsor: AstraZeneca
Heart Failure
Portugal
A Study in Healthy Volunteers and Patients With Mild Asthma to Investigate the Safety, Anti-inflammatory Effect of Inhaled AZD0449Completed
NCT03766399Phase 1Updated Aug 23, 2024
Sponsor: AstraZeneca
Asthma
Germany, New Zealand, United Kingdom
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.Completed
NCT00378482Phase 2Updated Aug 22, 2024
Sponsor: AstraZeneca
Colorectal Neoplasms · Melanoma · Prostatic Neoplasms · Renal Cell Carcinoma
United States, United Kingdom
Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPDRecruiting
NCT05507242Phase 2Updated Aug 21, 2024
Sponsor: Asger Sverrild
COPD · COPD Exacerbation · COPD Bronchitis · Airway Disease
Denmark, United Kingdom
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer PatientsCompleted
NCT03402841Phase 3Updated Aug 21, 2024
Sponsor: AstraZeneca
Non-Germline BRCA Mutated Ovarian Cancer
Austria, Belgium, Bulgaria, Canada, Czechia +14 more
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung CancerCompleted
NCT03421353Phase 1Updated Aug 21, 2024
Sponsor: AstraZeneca
Advanced Solid Tumours
United States
Screen CardRen - A Cross-sectional Observational Cohort StudyRecruiting
NCT06272578N/AUpdated Aug 21, 2024
Sponsor: Charite University, Berlin, Germany
Heart Failure · Chronic Kidney Diseases
Germany
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination GenesActive Not Recruiting
NCT03967938Phase 2Updated Aug 19, 2024
Sponsor: Universitair Ziekenhuis Brussel
Advanced Cancers Harbouring Mutations in HRG
Belgium
Primary Operation in SYnchronous meTastasized InVasivE Breast CancerCompleted
NCT01015625NAUpdated Aug 19, 2024
Sponsor: Austrian Breast & Colorectal Cancer Study Group
Synchronous Metastasized Breast Cancer · Circulating Tumor Cells
Austria
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)Completed
NCT04529564N/AUpdated Aug 13, 2024
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
Taiwan
PRagmatic Study Of Messaging to Providers of Patients With Heart Failure in Amsterdam UMCRecruiting
NCT06344910N/AUpdated Aug 9, 2024
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Heart Failure With Reduced Ejection Fraction
Netherlands
Virtual Personalized Exercise Program for Lung Cancer PatientsRecruiting
NCT06540495NAUpdated Aug 6, 2024
Sponsor: Northwell Health
Lung Cancer
United States
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid MalignanciesCompleted
NCT05469919Phase 1Updated Aug 2, 2024
Sponsor: AstraZeneca
Advanced Solid Malignancies
Japan
ACTIV-2: A Study for Outpatients With COVID-19Completed
NCT04518410Phase 2, Phase 3Updated Aug 2, 2024
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Coronavirus · Covid19
United States, Argentina, Brazil, Canada, Guatemala +4 more
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion BurdenTerminated
NCT03263091Phase 3Updated Aug 1, 2024
Sponsor: Kyntra Bio
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts) · Anemia
United States, Australia, Belgium, Canada, Denmark +11 more
The Impact of PCCM on Healthcare Among Asthma or Chronic Obstructive Pulmonary Disease (COPD) or Asthma-COPD Overlap PatientsCompleted
NCT04905420N/AUpdated Jul 31, 2024
Sponsor: AstraZeneca
Asthma · COPD · Asthma-COPD Overlap
China
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)Completed
NCT04724837Phase 2Updated Jul 30, 2024
Sponsor: AstraZeneca
Chronic Kidney Disease
United States, Argentina, Australia, Brazil, Bulgaria +14 more
Evaluate the Safety Profile of BGF MDI in Chinese Patients With COPD in Routine Clinical PracticeCompleted
NCT04536402N/AUpdated Jul 29, 2024
Sponsor: AstraZeneca
Chronic Obstructive Pulmonary Disease
China
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)Completed
NCT03830866Phase 3Updated Jul 26, 2024
Sponsor: AstraZeneca
Locally Advanced Cervical Cancer
United States, Brazil, Chile, China, Hungary +10 more
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompleted
NCT02352948Phase 3Updated Jul 26, 2024
Sponsor: AstraZeneca
Non - Small Cell Lung Cancer NSCLC
United States, Australia, Belgium, Bulgaria, Canada +21 more

Previous page Next page